Skip to Main Content

The False Claims Act & Health Care: 2018 Recoveries and 2019 Outlook

Date: 20 February 2019
By: Mark A. Rush, Mary Beth F. Johnston, John H. Lawrence, Jared A. Kephart, Samuel P. Reger

In 2018, the False Claims Act (“FCA”) continued to be one of the federal government’s (“Government”) preferred civil fraud enforcement tools across a variety of industries. The healthcare industry, however, remained the epicenter of FCA enforcement. Whistleblowers (“relators”), too, remained active in 2018, bringing an increased number of qui tam lawsuits against health care providers when compared with the previous year. Despite areas of uncertainty surrounding FCA actions in health care—from potentially shifting Department of Justice priorities and their impacts to the continued split amongst federal courts in their interpretation of Universal Health Servs., Inc. v. U.S. ex rel. Escobar and materiality—recent trends strongly suggest that health care-related FCA investigations, actions, and recoveries will remain robust in 2019.

This article analyzes FCA activity in 2018 by the numbers and considers how those numbers might shift in 2019.

To read the full alert, click here.

Mark A. Rush
Mark A. Rush
Pittsburgh
Washington DC
View
Mary Beth F. Johnston
Mary Beth F. Johnston
Research Triangle Park
View
John H. Lawrence
John H. Lawrence
Research Triangle Park
View

This publication/newsletter is for informational purposes and does not contain or convey legal advice. The information herein should not be used or relied upon in regard to any particular facts or circumstances without first consulting a lawyer. Any views expressed herein are those of the author(s) and not necessarily those of the law firm's clients.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel